DK1073467T3 - Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D - Google Patents

Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D

Info

Publication number
DK1073467T3
DK1073467T3 DK99914970T DK99914970T DK1073467T3 DK 1073467 T3 DK1073467 T3 DK 1073467T3 DK 99914970 T DK99914970 T DK 99914970T DK 99914970 T DK99914970 T DK 99914970T DK 1073467 T3 DK1073467 T3 DK 1073467T3
Authority
DK
Denmark
Prior art keywords
vitamin
compound
solvent formulations
formulations
solvent
Prior art date
Application number
DK99914970T
Other languages
Danish (da)
English (en)
Inventor
Lukchiu Li
Edward A Pec
Daniel H Robinson
Dennis A Stephens
Kathee Jantzi
Thomas B May
John P Oberdier
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22008769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1073467(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK1073467T3 publication Critical patent/DK1073467T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99914970T 1998-04-08 1999-03-22 Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D DK1073467T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/057,143 US6136799A (en) 1998-04-08 1998-04-08 Cosolvent formulations
EP99914970A EP1073467B1 (fr) 1998-04-08 1999-03-22 Formulations de co-solvants contenant de vitamin d

Publications (1)

Publication Number Publication Date
DK1073467T3 true DK1073467T3 (da) 2005-01-03

Family

ID=22008769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99914970T DK1073467T3 (da) 1998-04-08 1999-03-22 Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D

Country Status (11)

Country Link
US (2) US6136799A (fr)
EP (1) EP1073467B1 (fr)
JP (4) JP4664499B2 (fr)
AT (1) ATE275974T1 (fr)
AU (1) AU758989B2 (fr)
CA (1) CA2326198C (fr)
DE (1) DE69920201T2 (fr)
DK (1) DK1073467T3 (fr)
ES (1) ES2229693T3 (fr)
PT (1) PT1073467E (fr)
WO (1) WO1999051271A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US7189570B2 (en) * 2000-11-07 2007-03-13 North Carolina State University Putrescine-n-methyltransferase promoter
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
AU2003246829A1 (en) 2002-02-19 2003-09-09 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
CA2612604A1 (fr) * 2005-07-18 2007-01-25 Anchel Schwartz Preparation de paricalcitol
US20070166187A1 (en) * 2006-01-18 2007-07-19 Song Jing F Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
JP2009537530A (ja) * 2006-05-15 2009-10-29 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １α，２５−ジヒドロキシビタミンＤ３の肺送達および副甲状腺ホルモンまたはカルシトニンの同時投与
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
EP2545940A1 (fr) * 2011-07-14 2013-01-16 hameln rds gmbh Préparations parentérales
MX2015000076A (es) 2012-06-29 2015-04-10 Wisconsin Alumni Reasearch Foundation Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
ES2698403T3 (es) * 2012-12-27 2019-02-04 Pharmathen Sa Composición farmacéutica inyectable estable de agonista de receptor de vitamina D y proceso para su preparación
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
CN106265492B (zh) * 2015-06-04 2020-12-11 成都国为生物医药有限公司 一种含有帕立骨化醇的药物组合物及其制备方法
WO2018044468A1 (fr) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINAISON D'UNE FAIBLE DOSE DE 2-MÉTHYLÈNE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMINE D3 ET D'AGENTS CALCIMIMÉTIQUES POUR TRAITER UNE HYPERPARATHYROÏDIE SECONDAIRE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198391A (en) * 1973-07-20 1980-04-15 R. P. Scherer Ltd. Pharmaceutical compositions
US4212886A (en) * 1978-11-01 1980-07-15 Survival Technology, Inc. Stabilized benactyzine hydrochloride
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
DE3316510A1 (de) * 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
US4594340A (en) * 1984-11-29 1986-06-10 Hoffmann-La Roche Inc. 25,26-dehydro-1α,24R-dihydroxycholecalciferol and 25,26-dehydro-1α,24S-dihydroxycholecalciferol and the epimeric mixture
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
DK191889D0 (da) * 1989-04-20 1989-04-20 Bukh Meditec Kosmetisk middel
AU649057B2 (en) * 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
US5502224A (en) * 1991-06-04 1996-03-26 Marigen, S.A. Biotenside esters and phosphatides with vitamin-D and vitamin-E compounds
FR2677884B1 (fr) * 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
EP0591378B1 (fr) * 1991-06-28 1999-03-31 Hairbiotech, Inc. Procede de prevention et de traitement de l'alopecie induite par chimiotherapie
GB9201920D0 (en) * 1992-01-29 1992-03-18 Leo Pharm Prod Ltd Novel treatment i
JPH05246891A (ja) * 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
KR960013798B1 (ko) * 1992-04-24 1996-10-10 재단법인 한국전자통신연구소 평면 도파로형 공간 스위치
WO1996036340A1 (fr) * 1995-05-19 1996-11-21 Abbott Laboratories FORMULATIONS AQUEUSES STABLES DE 1α,25-DIHYDROXYCHOLECALCIFEROL POUR ADMINISTRATION PARENTERALE
US5597815A (en) * 1995-07-13 1997-01-28 Wisconsin Alumni Research Foundation Prevention of hyperphosphatemia in kidney disorder patients
US5834016A (en) * 1996-04-04 1998-11-10 Cilag Ag Liposome-based topical vitamin D formulation
ES2174388T3 (es) * 1997-06-27 2002-11-01 Akzo Nobel Nv Solucion liquida de medicamento para administracion oral.
CA2211949A1 (fr) * 1997-07-21 1999-01-29 David Farley Johnson Compositions non aqueuses a administrer par voie parenterale
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations

Also Published As

Publication number Publication date
WO1999051271A2 (fr) 1999-10-14
EP1073467A2 (fr) 2001-02-07
JP5548079B2 (ja) 2014-07-16
JP2011037860A (ja) 2011-02-24
JP5887368B2 (ja) 2016-03-16
JP4664499B2 (ja) 2011-04-06
ATE275974T1 (de) 2004-10-15
JP2002510652A (ja) 2002-04-09
AU3359899A (en) 1999-10-25
CA2326198C (fr) 2009-06-09
PT1073467E (pt) 2004-12-31
WO1999051271A3 (fr) 1999-11-18
ES2229693T3 (es) 2005-04-16
US6361758B1 (en) 2002-03-26
JP2016053046A (ja) 2016-04-14
AU758989B2 (en) 2003-04-03
DE69920201D1 (de) 2004-10-21
CA2326198A1 (fr) 1999-10-14
DE69920201T2 (de) 2005-09-29
EP1073467B1 (fr) 2004-09-15
JP2014129360A (ja) 2014-07-10
US6136799A (en) 2000-10-24

Similar Documents

Publication Publication Date Title
DK1073467T3 (da) Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D
FI964583A0 (fi) Tokoferolikoostumuksia biologisesti aktiivisten aineiden antamiseksi
DE69620877D1 (de) Arzneimittelformulierungen für il-12
DK0991407T3 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
DK0948965T3 (da) Stabile medicinske præparater indeholdende 4,5-epoxymorphinanderivater
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
BR9914251A (pt) Formulações orais de liberação sustentada
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
DK1021204T3 (da) Bioadhæsive præparater og fremgangsmåder til topisk administration af aktive midler
BR9611802A (pt) Composições farmacêuticas
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
PT1412384E (pt) Formulação estável de glp-1 modificado
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
SE8804629D0 (sv) New therapeutically active compounds
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
DE60019334D1 (de) Antivirale arznei
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
IS2258B (is) Setin tríasóló-pýridasín afleiða, lyfjasamsetningar gerðar úr henni
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DK1061938T3 (da) Orale sammensætninger med cytotoksiske proteiner i lav dosis
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.